13 March 2025
EMA: Warning about unregulated products in the EU
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) are warning the public about the dangers of unregulated advanced therapy medicinal products (ATMPs) which are currently being offered to patients in the European Union (EU). ATMPs are medicinal products which are based on genes, tissues or cells. They can offer important benefits to patients, if regulated. However, unregulated ATMPs have been marketed directly to patients, often when there is little to no evidence that the products work or are safe. The unregulated ATMPs could put patients at risk, causing serious side effects while not providing any benefits.
Fore more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting